Coronary atherosclerosis
Conditions
Interventions
None listed
Sponsors
Medisch Universitair Ziekenhuis Maastricht
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: General inclusion criteria: Able to provide informed consent Healthy Age between 18 and 75 years, For the stable ischemic heart disease (SIHD) population: Evidence of significant stable coronary artery disease defined by one of the below mentioned criteria *Occurrence of a MI more than one year ago. For MI, only type 1 MI (as described in the third universal definition of MI) will be considered *Coronary revascularization by either PCI or CABG more than one year ago. *Evidence of a significant (more than 50%) coronary stenosis on ICA or CCTA. *Evidence of loss of contractile myocardium consistent with MI on echo, CMR or CCTA. *Evidence of myocardial ischemia in two or more myocardial segments on stress echocardiography or perfusion imaging by SPECT or CMR, 2. Using oral aspirin as a anti platelet drug, For the healthy control population: - No additional inclusion criteria. Blood samples will be pre-treated with aspirin in vitro. - Treatment with a single dose of oral aspirin (100 mg) as a antiplatelet drug 1 day before blood drawing.
Exclusion criteria
Exclusion criteria: For the SIHD population: * Recent (within one year) myocardial infarction or revascularization by either CABG or PCI. * Unstable ischemic heart disease (CCS class 4) * Planned revascularization within one month, For the healthy control population: * Subjects currently under any medical care * Are currently known with any form of atherosclerotic disease * Are currently taking any antiplatelet drug, except for aspirin
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Platelet function as assessed by previously described multi-parameter outcome method (9 surfaces) will consist as the primary endpoint in this proof-of-concept study. Additionally, expression of key platelet receptors will be analyzed via flow cytometry as previously described to build understanding of underlying mechanisms of platelet reactivity. | — |
Secondary
| Measure | Time frame |
|---|---|
| * Platelet count, platelet mean volume (in blood) * Hb, Ht (in blood) * D-Dimer (in plasma) * Experimental/additional biomarkers of thrombogenicity clotting (platelet PF4 in plasma, platelet activation markers by flow cytometry of platelet-rich plasma) | — |
Countries
Netherlands
Outcome results
None listed